Chemotherapy-induced peripheral neuropathy (CIPN) symptoms include tingling, numbness, pain, or weakness - usually in the extremities. It is often called "chemo feet" or chemo hands".
This study used mice to induce the condition, then determine if daily administration of CBG had an effect on their pain sensitivity. It was published in the journal Pharmaceuticals in October 2023.
They used a common chemotherapy drug, cisplatin to induce the neuropathy over a period of 4 weeks. Afterwards, CBG was administered daily for 7 days and 14 days. Mechanical hypersensitivity due to CIPN was measured.
The CBG daily injected doses administered were 10 mg/kg for males and 15 mg/kg for females. The authors cited previous research indicating that female mice require larger doses than male mice in this model, so the authors let that guide their dosing decisions.
For a human weight of 75 kg (165 lbs) that would be equivalent to a CBG dose of about 750mg (male) and 1,125mg (female). This would be considered a large daily medicinal dose.
After just one hour on the first day of treatment with CBG:
- Both male and female mice "had significantly higher acute pain relief compared to the post-neuropathy readings".
- Pain levels in male mice returned to baseline (before chemo)
- Pain levels in female mice was reduced, but not all the way to baseline
An important aspect of their results show that the mice did not build up a tolerance for CBG after 14 days, meaning the same dose over time produced the same relief. This in contrast with THC. Results in many THC analgesic (pain relieving) studies show tolerance building up quickly.
In the authors' words:
We found that CBG treatment (i.p.) for 7 and 14 consecutive days significantly reduced mechanical hypersensitivity in male and female mice with CIPN and reduced pain sensitivity up to 60–70% of baseline levels (p < 0.001 for all), 24 h after the last injection.
chronic CBG administration can provide at least 24 h of antinociceptive effect in mice.
daily treatment with CBG did not evoke tolerance and did not incur significant weight change or adverse events.
These findings support the study of CBG as a long-lasting neuropathic pain therapy, which acts without tolerance in both males and females.
The full-text article is here at PubMed Central.
Nachnani R, Sepulveda DE, Booth JL, Zhou S, Graziane NM, Raup-Konsavage WM, Vrana KE. Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain. Pharmaceuticals (Basel). 2023 Oct 11;16(10):1442. doi: 10.3390/ph16101442. PMID: 37895913; PMCID: PMC10610438.